
1. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 
2.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial
tumors.

Routy B(1)(2)(3), Le Chatelier E(4), Derosa L(1)(2)(3), Duong CPM(1)(2)(5), Alou 
MT(1)(2)(3), Daillère R(1)(2)(3), Fluckiger A(1)(2)(5), Messaoudene M(1)(2),
Rauber C(1)(2)(3), Roberti MP(1)(2)(5), Fidelle M(1)(3)(5), Flament C(1)(2)(5),
Poirier-Colame V(1)(2)(5), Opolon P(6), Klein C(7), Iribarren
K(8)(9)(10)(11)(12), Mondragón L(8)(9)(10)(11)(12), Jacquelot N(1)(2)(3), Qu
B(1)(2)(3), Ferrere G(1)(2)(3), Clémenson C(1)(13), Mezquita L(1)(14), Masip
JR(1)(14), Naltet C(15), Brosseau S(15), Kaderbhai C(16), Richard C(16), Rizvi
H(17), Levenez F(4), Galleron N(4), Quinquis B(4), Pons N(4), Ryffel B(18),
Minard-Colin V(1)(19), Gonin P(1)(20), Soria JC(1)(14), Deutsch E(1)(13), Loriot 
Y(1)(3)(14), Ghiringhelli F(16), Zalcman G(15), Goldwasser F(9)(21)(22), Escudier
B(1)(14)(23), Hellmann MD(24)(25), Eggermont A(1)(2)(14), Raoult D(26), Albiges
L(1)(3)(14), Kroemer G(27)(9)(10)(11)(12)(28)(29), Zitvogel L(30)(2)(3)(5).

Author information: 
(1)Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
(2)Institut National de la Santé et de la Recherche Medicale (INSERM) U1015 and
Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.
(3)Univ. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
(4)MGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
(5)Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
Villejuif, France.
(6)Gustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif,
France.
(7)Centre de Recherche des Cordeliers, INSERM, Université Paris Descartes,
Sorbonne Paris Cité, UMRS 1138, Université Pierre et Marie Curie Université Paris
06, Sorbonne Universités, Paris, France.
(8)Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
(9)Paris Descartes University, Sorbonne Paris Cité, Paris, France.
(10)Equipe 11 Labellisée-Ligue Nationale contre le Cancer, Centre de Recherche
des Cordeliers, Paris, France.
(11)INSERM U1138, Paris, France.
(12)Université Pierre et Marie Curie, Paris, France.
(13)Department of Radiation Oncology, INSERM U1030, and Molecular Radiotherapy,
Gustave Roussy, Université Paris-Saclay, F-94805 Villejuif, France.
(14)Department of Medical Oncology, Gustave Roussy, Villejuif, France.
(15)Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude
Bernard, AP-HP, Université Paris-Diderot, Paris, France.
(16)Department of Medical Oncology, Center GF Leclerc, Dijon, France.
(17)Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering
Cancer Center, New York, NY, USA.
(18)Molecular Immunology and Embryology, UMR 7355, CNRS, University of Orleans,
Orléans, France.
(19)Department of Pediatric Oncology, GRCC, Villejuif, France.
(20)Preclinical Research Platform, GRCC, Villejuif, France.
(21)Department of Medical Oncology, Cochin Hospital, Assistance Publique-Hôpitaux
de Paris, Paris, France.
(22)Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris,
France.
(23)INSERM U981, GRCC, Villejuif, France.
(24)Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering
Cancer Center, New York, NY, USA.
(25)Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
(26)URMITE, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095,
IHU-Méditerranée Infection, 13005 Marseille, France.
(27)Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.
(28)Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance
Publique-Hôpitaux de Paris, Paris, France.
(29)Department of Women's and Children's Health, Karolinska University Hospital, 
17176 Stockholm, Sweden.
(30)Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.

Comment in
    Nat Rev Clin Oncol. 2018 Jan;15(1):6-7.
    Science. 2018 Jan 5;359(6371):32-34.
    Cell Res. 2018 Mar;28(3):263-264.
    Nat Rev Microbiol. 2018 Mar;16(3):121.
    Sci Immunol. 2018 Feb 2;3(20):.
    Gastroenterology. 2018 May;154(6):1845-1847.
    Clin Chem. 2018 Sep;64(9):1280-1283.
    Eur Urol. 2018 Oct;74(4):521-522.
    Transl Cancer Res. 2018 Jun;7(Suppl 5):S608-S610.
    Nat Med. 2018 Dec;24(12):1782.
    Bull Cancer. 2019 Jan;106(1):10.
    Hepatobiliary Surg Nutr. 2018 Dec;7(6):479-480.
    Hepatobiliary Surg Nutr. 2018 Dec;7(6):481-483.

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce
sustained clinical responses in a sizable minority of cancer patients. We found
that primary resistance to ICIs can be attributed to abnormal gut microbiome
composition. Antibiotics inhibited the clinical benefit of ICIs in patients with 
advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who 
responded to ICIs into germ-free or antibiotic-treated mice ameliorated the
antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients
failed to do so. Metagenomics of patient stool samples at diagnosis revealed
correlations between clinical responses to ICIs and the relative abundance of
Akkermansia muciniphila Oral supplementation with A. muciniphila after FMT with
nonresponder feces restored the efficacy of PD-1 blockade in an
interleukin-12-dependent manner by increasing the recruitment of CCR9+CXCR3+CD4+ 
T lymphocytes into mouse tumor beds.

Copyright © 2018, American Association for the Advancement of Science.

DOI: 10.1126/science.aan3706 
PMID: 29097494  [Indexed for MEDLINE]

